CenterBook Partners
ACAD icon

CenterBook Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

CenterBook Partners’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-68,928
Closed -$1.74M – 857
2026
Q2 		$1.74M Buy
68,928
+49,192
+249% +$1.08M 0.09% 259
2026
Q1 		$439K Buy
+19,736
New +$472K 0.02% 510
2025
Q4 		– Sell
-11,152
Closed -$238K – 543
2025
Q3 		$238K Buy
+11,152
New +$264K 0.01% 533

Other funds holding ACAD

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Panagora Asset Management
Panagora Asset Management Boston, Massachusetts $33.2B AUM 43.67% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

CenterBook Partners's ACAD Position: Q3 2026 in Review

CenterBook Partners sold out of Acadia Pharmaceuticals (ACAD) in Q3 2026, closing a stake of 68,928 shares — an estimated $1.74M sold.

CenterBook Partners first reported a position in ACAD in Q3 2025 and held it in 3 quarters. The position peaked at $1.74M in Q2 2026. 215 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.

  • CenterBook Partners reported no remaining Acadia Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • CenterBook Partners sold 68,928 Acadia Pharmaceuticals shares in Q3 2026, an estimated $1.74M.
  • CenterBook Partners first reported a position in Acadia Pharmaceuticals in Q3 2025 and held it in 3 quarters.
  • CenterBook Partners's Acadia Pharmaceuticals position peaked at $1.74M in Q2 2026.
  • 215 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.

Based on CenterBook Partners's 13F filing for Q3 2026, filed 2 Nov 2026.